Latest Therapies under investigation for multiple sclerosis Stories
WASHINGTON - The government on Friday began posting a list of prescription drugs under investigation for potential safety problems in an effort to better inform doctors and patients. The first list is a bare-bones compilation naming 20 medications and the potential issue for each.
Elan and Biogen Idec have initiated the first clinical trial of Tysabri in oncology. The first dose of Tysabri was administered earlier in the trial.
Research and Markets (http://www.researchandmarkets.com/research/f0d42d/cns_drug_discoveri) has announced the addition of the "CNS Drug Discoveries: Multiple Sclerosis Chapter" report to their offering. This chapter of CNS Drug Discoveries focuses on the multiple sclerosis market.
Biogen Idec has completed enrollment in the Assurance trial, a long-term follow-up study which will assess up to 15 years of Avonex treatment in an effort to provide detailed data on the long-term efficacy of the drug.
CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases.
CAMBRIDGE, Mass., July 16 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced that it has completed a second close of $8.9 million of its Series D preferred stock offering with its investor syndicate led by New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital, and its Chairman of the Board.
Teva Pharmaceutical Industries and Active Biotech have announced that patients are being enrolled for the Bravo Phase III pivotal trial.
Theravance has announced the positive results from a Phase I study designed to assess the safety, tolerability and pharmacokinetics of an investigational inhaled long-acting muscarinic antagonist, GSK1160724/TD-4208, for the treatment of chronic obstructive pulmonary disease.
Opexa Therapeutics has announced that the data safety monitoring board overseeing the on-going Phase IIb clinical study of Tovaxin has recommended that the trial continue unmodified.
Teva Pharmaceutical Industries has reported results from a Phase III study designed to assess the efficacy, safety and tolerability of glatiramer acetate 40mg as compared to the approved Copaxone 20mg in the treatment of relapsing-remitting multiple sclerosis.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.